About Pantrone

Pantrone Consulting Co. Ltd. was established in 2019 and is a Contract Research Organization (CRO) specializing in cell therapy clinical trials. Pantrone is composed of top-notch doctoral and master’s graduates from top-ranking domestic and international universities.

Dr. Pan, the founder, graduated from the Department of Microbiology at National Taiwan University’s College of Medicine and has over a decade of experience in the biotechnology industry. His expertise includes the development of cell therapy products and small molecule drugs, as well as extensive experience in clinical trials, startups, and biotech investments. Our mission is to assist biotech companies in developing new drugs and accelerating their entry into clinical trials to save more lives.

Pantrone has successfully assisted in obtaining multiple approvals for Investigational New Drug (IND) applications from the U.S. Food and Drug Administration (FDA).

We provide the most professional services for clinical trials of cell products. In 2023, the first Taiwan-based allogeneic chimeric antigen receptor T-cell (Car-T) therapy has received IND approval in the United States by choosing Pantrone as their CRO partner. We believe Pantrone is by no doubt your best choice for cell product development.